secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001104659-26-001125
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana acquired by Day One for $25.00/share plus CVR up to $30.25
------------------------------------------------------------------

- Tender offer expired Jan 5, 2026; 60.57% of shares tendered; merger closed Jan 6, 2026.
- Consideration: $25.00 per share cash plus one non-tradeable CVR per share with potential milestone payments up to $30.25.
- CVR milestones include FDA approval for ACC-1 ($9.00), first patient dosed ($4.00), and net sales thresholds; total max $30.25 per CVR.
- All pre-merger directors resigned; Charles N. York II and Adam Dubow appointed directors; stock delisted from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465926001125/0001104659-26-001125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465926001125/tm261736d24_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer